Artenimol
Sickle Cell Anemia in Children
Liverpool School of Tropical MedicineSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Sickle Cell Anemia in Children cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PIPERAQUINOLINE Liverpool School of Tropical Medicine | Phase 3 | BB |
Same molecule, other indications
Artenimol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →